hepatitis B adjuvanted vaccine (HBAI20)
/ CyTuVax
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 11, 2021
Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: double-blinded, randomised, controlled phase 2 trial.
(PubMed, Liver Int)
- "In this group of hepatitis B vaccine non-responders, the HBAI20 vaccine demonstrated a higher seroprotection rate when adjusting for stratification factors and a similar safety profile compared to the licensed recombinant HBVaxPro®-10µg."
Clinical • Journal • P2 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • IL2
1 to 1
Of
1
Go to page
1